KRAS-Mutated Non-Small Cell Lung Cancer - Beverly Hills CA (Metro Los Angeles)

Summary:

From Clinicaltrials.gov

Study Type: Interventional  (Clinical Trial)

Estimated Enrollment  :44 participants

Allocation:N/A

Intervention Model:Single Group Assignment

Masking:None (Open Label)

Primary Purpose:Treatment

Official Title:A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer

Qualified Participants Must:

• Have histologically or cytologically confirmed progressive or metastatic NSCLC with documented KRAS-mutant genotype, who have failed standard treatment and have no other effective treatment available or appropriate for the patient.

Qualified Participants May Receive:

Experimental: NBF-006

Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks